AVeta Medical strengthens their Board
AVeta Medical Establishes Board of Directors with Experienced Leaders.
We are excited to announce the establishment of our Board of Directors, comprising highly experienced professionals in the medical and healthcare industries. This strategic move is aimed at preparing for the commercialisation of AVeta Medical's innovative therapy.
Chairperson of the Board
Karen Noblett, M.D., has been appointed as the new Chairperson of the Board. Dr. Noblett is Board Certified in OB/GYN and Female Pelvic Medicine and Reconstructive Surgery. With a distinguished career in academic medicine, she brings invaluable expertise to our team.
Joining the board alongside Dr. Noblett are Jane Kiernan and Eileen Duffy. Jane Kiernan brings over 30 years of executive and management leadership in healthcare. She is the cofounder of K2 Biotechnology Ventures and has previously served as the CEO of Salter Labs and on the Board of Directors of Nasdaq-listed American Medical Systems (AMS).
Eileen Duffy brings to the board over 25 years of global commercial experience in the Lifesciences and Medtech Industries, through executive leadership roles at Baxter International , and Aerogen, Irelands largest indigenous medical device company , She brings deep commercial experience and a proven track record of building and growing companies across therapeutic areas and geographies. Eileen currently serves on the Board of Directors of Sarnova, a Patricia Industries company. Eileen has also held various global senior executive leadership positions at Baxter International where she worked with Jane Kiernan. She received her Master’s in Business Administration (MBA) from University College Dublin (Ireland) and holds a Diploma in Corporate Governance from The Corporate Governance Institute.
These new board members join AVeta Medical's Founder, Paula Newell, and Co-Founder and CEO, Brian Ledwith, to guide the company through its next phase of growth and commercialization. In addition to this great news we are well on the way to meet our funding targets for completing our RCT clinical trials . Please see our campaign. https://lnkd.in/dqhPVwYr
